Neurocognitive predictors of functional outcome two to 13years after identification as ultra-high risk for psychosis

A Lin; SJ Wood; B Nelson; WJ Brewer; D Spiliotacopoulos; A Bruxner; C Broussard; C Pantelis; AR Yung

Journal article

Neurocognitive predictors of functional outcome two to 13years after identification as ultra-high risk for psychosis

A Lin, SJ Wood, B Nelson, WJ Brewer, D Spiliotacopoulos, A Bruxner, C Broussard, C Pantelis, AR Yung

Schizophrenia Research | ELSEVIER | Published : 2011

DOI: 10.1016/j.schres.2011.06.014

Abstract

Background and aim: Little is known about the relationship between neurocognitive performance and functional outcome before the onset of frank psychosis. This longitudinal study aimed to investigate neurocognitive predictors of poor functional outcome in a group identified as ultra-high risk (UHR) for psychosis between two and 13. years prior. Method: Individuals (N=230) identified as UHR for psychosis at the PACE Clinic in Melbourne completed assessment of psychopathology, functioning and neurocognition at baseline and follow-up. The mean length of follow-up was 7.26. years (SD 3.05). Results: Forty-one individuals with the poorest functional outcome were identified. Only 48.8% of this grou..

View full abstract

University of Melbourne Researchers

Stephen Wood Author

Barnaby Nelson Author

Christos Pantelis Author

Related Projects (2)

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

EMERGING SEVERE MENTAL ILLNESS IN YOUNG PEOPLE

Mental disorders, such as psychotic and severe mood disorders, are the largest cause of disability in Australia. However, there is still lit..

Grants

Funding Acknowledgements

This project was supported by NHMRC Program Grants (#350241 and 566529) and the Colonial Foundation. SJW and WJB are supported by National Health and Medical Research Council (NHMRC) Career Development Awards. BN is supported by a Ronald Phillip Griffith Fellowship and a NARSAD Young Investigator Award.CP has received research funding from Janssen-Cilag, Eli-Lilly, Hospira (Mayne) and AstraZeneca, and has acted as a consultant for Janssen-Cilag, Eli-Lilly, Hospira (Mayne), AstraZeneca, Pfizer, Schering and Plough. ARY has received honoraria and travel support from AstraZeneca, Eli-Lilly, Bristol Meyer Squibb and Janssen-Cilag. Other authors have no conflicts of interest.